Michael Burger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael Burger has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Christophe Leroux
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich 8093 Zurich, Switzerland
12 shared publications David Scherer
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
5 shared publicationsSteffen Honrath
ETH Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
5 shared publications- Christina Greitens
ETH Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
4 shared publications - Alexander Klipp
ETH Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
2 shared publications Christina Greitens
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, 8093 Zurich, Switzerland
2 shared publications
Latest Publications
- Open Access
- 21 November 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35
VRK1 co-delivery mitigates DNA clustering by BAF in TFAMoplex transfection
- 21 November 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35
Open AccessVRK1 co-delivery mitigates DNA clustering by BAF in TFAMoplex transfection
- Open Access
- 18 June 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 681, 125855
The intracellular journey of DNA delivered with the protein-based transfection system TFAMoplex and Lipofectamine
- 18 June 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 681, 125855
Open AccessThe intracellular journey of DNA delivered with the protein-based transfection system TFAMoplex and Lipofectamine
- Open Access
- 17 June 2025
- Published by Elsevier in Trends in Biotechnology
- Vol. 43 (9) , 2362-2377
Rapid selection of transgenic mammalian cells via diphtheria toxin resistance
- 17 June 2025
- Published by Elsevier in Trends in Biotechnology
- Vol. 43 (9) , 2362-2377
Open AccessRapid selection of transgenic mammalian cells via diphtheria toxin resistance
- Open Access
- 9 June 2025
- Published by Elsevier in Cell Reports Methods
- Vol. 5 (6) , 101073
Encapsulation of protein/DNA complexes into unilamellar liposomes via annexin-mediated membrane recruitment and sonication
- 9 June 2025
- Published by Elsevier in Cell Reports Methods
- Vol. 5 (6) , 101073
Open AccessEncapsulation of protein/DNA complexes into unilamellar liposomes via annexin-mediated membrane recruitment and sonication
- Open Access
- 29 May 2025
- Published by Elsevier in Journal of Molecular Biology
- Vol. 437 (17) , 169239
VWA7 – A Putative Human Phosphatidylcholine-specific Phospholipase C
- 29 May 2025
- Published by Elsevier in Journal of Molecular Biology
- Vol. 437 (17) , 169239
Open AccessVWA7 – A Putative Human Phosphatidylcholine-specific Phospholipase C
- Open Access
- 28 March 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (2)
Closing the gap: Nonviral TFAMoplex transfection boosted by bZIP domains compared to AAV-mediated transduction
- 28 March 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (2)
Open AccessClosing the gap: Nonviral TFAMoplex transfection boosted by bZIP domains compared to AAV-mediated transduction
- Open Access
- 25 February 2025
- Published by Wiley in Advanced Science
- Vol. 12 (15) , e2410815
Modular Calcium‐Responsive and CD9‐Targeted Phospholipase System Enhancing Endosomal Escape for DNA Delivery
Gene delivery systems must overcome multiple barriers, with endosomal escape representing a prominent obstacle. We have previously shown that a bacterial phospholipase C (PLC) enabled endosomal escape of a non‐viral protein‐based DNA delivery system termed TFAMoplex. Building upon this, this work introduces a calcium‐responsive system designed to enhance endosomal escape through non‐covalent capturing of PLC to the TFAMoplex followed by its release within endosomes and nanobody‐mediated targeting to the endosomal membrane. This approach leads to improved TFAMoplexes enabling transfection of HeLa cells in full serum with a half maximal effective concentration (EC50) of less than 200 ng DNA per mL serum, using only 5 nM PLC. Particularly, the modular capture, release and targeting system could potentially be adapted to other delivery agents previously constrained by poor endosomal escape. These findings present a promising strategy to achieve efficient endosomal escape, offering prospects for improved delivery of macromolecules, in particular nucleic acids.
- 25 February 2025
- Published by Wiley in Advanced Science
- Vol. 12 (15) , e2410815
Open AccessModular Calcium‐Responsive and CD9‐Targeted Phospholipase System Enhancing Endosomal Escape for DNA Delivery
Gene delivery systems must overcome multiple barriers, with endosomal escape representing a prominent obstacle. We have previously shown that a bacterial phospholipase C (PLC) enabled endosomal escape of a non‐viral protein‐based DNA delivery system termed TFAMoplex. Building upon this, this work introduces a calcium‐responsive system designed to enhance endosomal escape through non‐covalent capturing of PLC to the TFAMoplex followed by its release within endosomes and nanobody‐mediated targeting to the endosomal membrane. This approach leads to improved TFAMoplexes enabling transfection of HeLa cells in full serum with a half maximal effective concentration (EC50) of less than 200 ng DNA per mL serum, using only 5 nM PLC. Particularly, the modular capture, release and targeting system could potentially be adapted to other delivery agents previously constrained by poor endosomal escape. These findings present a promising strategy to achieve efficient endosomal escape, offering prospects for improved delivery of macromolecules, in particular nucleic acids.
- Open Access
- 27 November 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 104
3D printed pH-responsive colonic capsules for the delivery of live aqueous bacterial suspensions
- 27 November 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 104
Open Access3D printed pH-responsive colonic capsules for the delivery of live aqueous bacterial suspensions
- Open Access
Rapid selection of transgenic mammalian cells via diphtheria toxin resistance
The ability to generate stable transgenic mammalian cell lines is crucial to the investigation of gene functions and the production of recombinant proteins. Currently, mammalian cells can be readily transfected in cell culture settings via both viral and nonviral vectors to induce transgene expression. However, there is an unmet need for efficient selection of transfected cells, since current methods involve rather inefficient antibiotic selection protocols or require the coexpression of fluorescent marker proteins, followed by laborious cell sorting procedures. Our aim was to implement a rapid and efficient in situ selection approach for transgene-expressing human cells, using an engineered diphtheria toxin (DT) resistance-based selection, referred to as selecDT. We demonstrated that selecDT is expressed on the surface of modified human cells, provides efficient protection from DT by inactivating its uptake receptor, and, therefore, enables selection. Current antibiotic-based methods require selection periods of more than a week and often achieve only limited cell enrichment. With selecDT, one day of selection is sufficient to obtain nearly 100% enrichment. The DT resistance described herein may thus positively impact biotechnological processes and biomedical research.
Open AccessRapid selection of transgenic mammalian cells via diphtheria toxin resistance
The ability to generate stable transgenic mammalian cell lines is crucial to the investigation of gene functions and the production of recombinant proteins. Currently, mammalian cells can be readily transfected in cell culture settings via both viral and nonviral vectors to induce transgene expression. However, there is an unmet need for efficient selection of transfected cells, since current methods involve rather inefficient antibiotic selection protocols or require the coexpression of fluorescent marker proteins, followed by laborious cell sorting procedures. Our aim was to implement a rapid and efficient in situ selection approach for transgene-expressing human cells, using an engineered diphtheria toxin (DT) resistance-based selection, referred to as selecDT. We demonstrated that selecDT is expressed on the surface of modified human cells, provides efficient protection from DT by inactivating its uptake receptor, and, therefore, enables selection. Current antibiotic-based methods require selection periods of more than a week and often achieve only limited cell enrichment. With selecDT, one day of selection is sufficient to obtain nearly 100% enrichment. The DT resistance described herein may thus positively impact biotechnological processes and biomedical research.
- Open Access
- 18 July 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 373, 252-264
Interaction proteomics analysis to provide insight into TFAMoplex-mediated transfection
- 18 July 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 373, 252-264
Open AccessInteraction proteomics analysis to provide insight into TFAMoplex-mediated transfection